key: cord-0878231-ac3sv3v9
authors: Tariq, Raseen; Saha, Srishti; Furqan, Fateeha; Pardi, Darrell; Khanna, Sahil
title: In Reply - Lack of Significant Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-Analysis Based on Adjusted Effect Estimates
date: 2021-04-21
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.04.010
sha: 5f1784900125bdac792cbf265bdf19bb1b6da25d
doc_id: 878231
cord_uid: ac3sv3v9

nan

To the Editor: We appreciate the interest of Li et al 1 in our systematic review and meta-analysis evaluating the prevalence of gastrointestinal (GI) symptoms and the association with mortality in patients with coronavirus disease 2019 (COVID-19). 2 Li et al performed an updated metaanalysis with a larger sample size to explore the impact of GI symptoms on mortality associated with COVID-19. Based on adjusted effect estimates (controlling for potential confounders), they found no association between GI symptoms and mortality (pooled effect = 0.93, 95% CI: 0.75-1.16, P = .535). The results remain consistent on multiple subgroup analyses. Due to lack of risk of bias assessment of included studies, it is hard to ascertain the quality of included evidence.

Moreover, different follow-up duration of the included studies could impact mortality estimates.

The results of their pooled meta-analysis are similar to our study with some differences. 2 Due to lack of reporting of uniform data on confounders and comorbidities, our findings were based on crude estimates. Since then, additional studies have been published with COVID-19 being a widely researched topic. We completely agree that certain risk factors, including age, gender and comorbidities could impact the mortality in patients with COVID-19 patients. 3

Another similar meta-analysis suggested an increased risk of severe COVID 19 with GI symptoms, compared with those without GI symptoms (odds ratio 3.97 [95% CI 1.49-10.62]; p=0,006]. 4 Patients with GI symptoms conceivably had delayed COVID-19 diagnosis which may have led to severe COVID-19 and worse outcomes. A recent study found that despite the presence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antigens in the intestinal tissue, the inflammatory response observed was mild. The authors also found a significant reduction in disease severity and mortality in patients presenting with any GI symptoms compared to those without GI symptoms, independent of age, gender and comorbid conditions. 5 Based on current literature, it can be proposed that COVID-19 patients with GI symptoms do

Lack of significant association between gastrointestinal symptoms and COVID-19 mortality: An updated meta-analysis based on adjusted effect estimates

Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Metaanalysis

Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms